Discovery and Characterization of Small Molecular Weight Metallocarboxypeptidase Inhibitors

Total Page:16

File Type:pdf, Size:1020Kb

Discovery and Characterization of Small Molecular Weight Metallocarboxypeptidase Inhibitors Departament de Bioquímica i Biologia Molecular Discovery and characterization of small molecular weight metallocarboxypeptidase inhibitors Daniel Fernández Doctoral Thesis 2009 Departament de Bioquímica i Biologia Molecular Discovery and characterization of small molecular weight metallocarboxypeptidase inhibitors Doctoral Thesis presented by Daniel Fernández to fulfill the Ph. D. degree in Biotechnology from the Universitat Autònoma de Barcelona Daniel Fernández Francesc X. Avilés Puigvert Josep Vendrell Roca Thesis co-directors Barcelona, 2009 A mis padres A Silvia Index Preface List of published material Abbreviations Introduction 1 The proteases 1 1.1 Types of proteases 1 1.2 The metallocarboxypeptidases 2 1.3 Inhibitors of CPs from natural sources 4 1.4 CPA as a model metalloprotease 5 2 Biology - carboxypeptidases 7 in health and disease 2.1 CP activities in the gastrointestinal tract 7 2.2 CP roles in acute pancreatitis and cancer 8 2.3 Extra-pancreatic carboxypeptidases 9 2.4 A CPB-like antifibrinolytic 10 3 Biotechnology - from protein 13 hydrolyzates to cancer therapy 4 Organic synthetic inhibitors 15 of caboxypeptidases 4.1 Ground-state inhibitors 16 4.2 Transition-state inhibitors 21 Objectives 23 Results and Discussion 5 Discovery of novel inhibitors 25 5.1 The arginine derivatives (family DF1) 26 5.2 Thioxophosphoranyl oxiranes (DF2) and 28 cyclobutane β-peptides (DF3) 5.3 L-alanyl derivatives (DF4) and 33 organosilicon compounds (DF5) 5.4 Peptoids (DF6) 37 5.5 Oxadiazoles (DF7) 40 6 Bioinformatics 43 6.1 The crystal structure pool 43 6.2 Interactions of the catalytic domain 44 6.3 Nature of the ODA patches 46 6.4 Predictive success of the method 47 6.5 Surface area of the ODA patches 49 6.6 Sequence-structure relationships 50 6.7 Protein-ligand relationships 54 6.8 Regionalization of the ODA patches 55 6.9 Accuracy of the predictions 57 6.10 Potential roles of the ODA patches 60 7 Crystallization and 65 X-ray diffraction studies 7.1 Structure of a new CPB crystal form 66 7.2 Assignment of residues 68 7.3 Comparison to the known tetragonal crystal 70 7.4 The aromatic cluster 72 7.5 The role of Tyr248 and its flanking region 75 7.6 CPA crystallization 80 7.7 The complex of CPA and 81 a mechanism-based inhibitor 7.8 Conformational changes 86 7.9 The zinc environment 87 7.10 The ligand structure 88 Overall discussion 91 Conclusions 97 8 Methods 99 8.1 General materials and media 99 8.2 Protein handling 101 8.3 Kinetic measurements and data treatment 103 8.4 X-ray crystallography – crystallogenesis 105 8.5 X-ray crystallography – data handling 107 8.6 X-ray crystallography – structure solution 110 8.7 Bioinformatics – the ODA method 114 8.8 Bioinformatics – virtual screening 117 8.9 Bioinformatics – resources 120 Bibliography 121 Acknowledgements 137 Publications 139 Preface When I started working at our group at the UAB, I was not aware of the impact this endeavor would be operating upon me. Peptidases are proteins that have to be carefully faced up with because of their natural job of degrading other proteins. Therefore, finding a means to modulate their activity seemed both a bewildering and challenging task. And also a top-motivating one... Five years later this feeling persists. Although some advances have been made, there seems to be no efficient means to modulate carboxypeptidase action by designed small molecular weight drugs, and therefore to shift the balance from disease to health. However, some things need time... Peptidases let me introduce into molecular and structural biology, and bioinformatics. More importantly, they allowed me to meet a fascinating new world, paradoxically the “Old world”, in a journey to a new Continent, country and nation. To a lovely city and a stimulating environment. As with peptidases, I’ve made countless people discoveries. The latter are of course not measurable by any scientific method, but constitute an important part of life. However, as this document is not intended to be a biographical account, I’ll focus on Science. Notice about the format of this Thesis At the time of writing, parts of the work done during my Ph. D. have either been published, “lost” in the review process, or remain inedit. Thus, the experimental results are organized with a general sense in Chapters 5 to 7, to cover the different approaches employed. These Chapters are not intended as a compendium of publications. Published work is included in a separate section. The same was applied to Methods. Chapter 8 covers in a general way all aspects of the techniques used, while the peculiarities of each of them can be found in the attached papers. I’ve tried to organize all parts in a well-balanced structure. Whenever possible, I’ve summarized all the information available. To begin with, Chapters 1 to 4 review background information. This is intended as a general Introduction. A brief introductory comment is included as a reference in each section of Chapters 5 to 7. Information on each specific topic can be found in the attached published material. The Discussion and Conclusions are also general. List of published material 1 Articles described in this Thesis Fernández DD, Testero S, Vendrell J, Avilés FX, Mobashery S. (2010). Chem Biol Drug Des, in press* *Our work was awarded the cover of volume 74 to appear in Feb/2010 Fernández DD, Boix E, Pallarès I, Avilés FX, Vendrell J. (2009). Biopolymers, in press Fernández DD, Avilés FX, Vendrell J. (2009). Chem Biol Drug Des 73:75-82 Fernández DD, Torres E, Avilés FX, Ortuño RM, Vendrell J. (2009). Bioorg Med Chem 17:3824-3828 Fernández DD, Avilés FX, Vendrell J. (2009). Eur J Med Chem 44:3266-3271 Fernández DD, Illa O, Avilés FX, Branchadell V, Vendrell J, Ortuño RM. (2008). Bioorg Med Chem 14:4823-4828 Fernández DD, Vendrell J, Avilés FX, Fernández-Recio J. (2007). Proteins: Structure, Function, and Bioinformatics 60:131-144 2 Inedit works Fernández DD, Montenegro M, Avilés FX, Vendrell J, García-Viloca M. (2009). In preparation Fernández DD, Avilés FX, Vendrell J, Pérez-Trujillo M, Parella T. (2009). Submitted to J Inorg Biochem 3 Crystal structures validated and deposited with major databases Cambridge Crystallographic Data Centre (CCDC) 1. deposit number: 671796 Protein Data Bank (PDB) 1. ID: 2v77 2. ID: 3glj 3. ID: 3hlp 4. ID: 3huv 5. ID: 3i1u 4 Other articles Pallarès I, Fernández DD, Comellas-Bigler M, Fernández-Recio J, Ventura S, Avilés FX, Bode W, Vendrell J. (2008). Acta Crystallogr D Biol Crystallogr 64::784-791 Niemirowicz G, Fernández DD, Solá M, Cazzulo JJ, Avilés FX, Gomis-Rüth FX. (2008). Mol Microbiol 70:853-866 Bayés A, Fernández DD, Solá M, Marrero A, García-Piqué S, Avilés FX, Vendrell J, Gomis-Rüth FX. (2007). Biochemistry 46:6921-6930 Abbreviations ACE, angiotensin-converting enzyme ADEPT, antibody-directed enzyme prodrug therapy Ala, alanine Arg, arginine Asn, asparagine Asp, aspartic acid bCPA, bovine carboxypeptidase A (= CPA) bCPA1, bovine carboxypeptidase A1 (= bCPA) bPCPA1, bovine procarboxypeptidase A1 BzlSA, 2-benzylsuccinic acid CBP, cyclobutane β-peptide CCP, cytosolic carboxypeptidase CP, carboxypeptidase CPA, carboxypeptidase A CPB, pancreas carboxypeptidase B ( = CPB1) CPD, carboxypeptidase D CPE, carboxypeptidase E CPM, carboxypeptidase M CPN, carboxypeptidase N CPU, human plasma CPB ( = TAFI/CPR/CPB2) CPZ, carboxypeptidase Z CTGC, chymotrypsinogen C Cys, cysteine Da, dalton dCPD, domain II of duck carboxypeptidase D ( = CPD) DMSO, dimethylsulfoxide ECI, endogenous carboxypeptidase inhibitor (= latexin) GEMSA, 2-(2-guanidinoethylthio)succinic acid Gln, glutamine Glu, glutamic acid Gly, glycine HaCPA, CPA from cotton bollworm (Helicoverpa armigera) hCPA1, human carboxypeptidase A1 hCPA2, human carboxypeptidase A2 hCPA4, human carboxypeptidase A4 hCPB, human pancreas CPB ( = CPB/CPB1) hCPU, human plasma CPB (= TAFI/CPR/CPB2) hCPM, human carboxypeptidase M ( = CPM) His, histidine hPCPA1, human procarboxypeptidase A1 HzCPB, CPB from corn earworm (Helicoverpa zea) Ile, isoleucine iPr, iso-propyl LCI, leech carboxypeptidase inhibitor Leu, leucine Lys, lysine MD, molecular dynamics MES, 2-(N-morpholino)ethanesulfonic acid Met, metionine MMP, matrix metalloproteinase MR, molecular replacement MW, molecular weight ODA, Optimal Docking Area PCI, potato carboxypeptidase inhibitor PCP, procarboxypeptidase pCPB, porcine pancreas carboxypeptidase B PDB, Protein Data Bank Phe, phenylalanine PPE, proproteinase E Pro, proline SDS, sodium dodecyl sulfate Ser, serine Tris, 2-amino-2-(hydroxymethyl)propane-1,3-diol TAFI, thrombin-activable fibrinolysis inhibitor (=CPU/CPR/plasma CPB/CPB2) TCI, tick carboxypeptidase inhibitor TcMCP-1, metallocarboxypeptidase 1 from Trypanosoma cruzi TcMCP-2, metallocarboxypeptidase 2 from Trypanosoma cruzi Thr, threonine TvCPT, carboxypeptidase T fom Thermoactynomices vulgaris Trp, tryptophan Tyr, tyrosine Val, valine Z , carbobenzoxy Introduction 1 The proteases Proteases are proteins that catalyze the hydrolysis of the C-N bond, or peptide bond, of protein and peptide substrates and are therefore called peptidases as well. Proteases were recognized early in the history of biochemistry. In the nineteenth century, one primary focus of research was on digestive proteases like pepsin and trypsin. Another important digestive protease named carboxypeptidase was isolated and characterized in the last years of the second decade of the twentieth century. Digestive proteases are located in the gastro-intestinal tract and are mainly responsible for the digestion of food proteins (Erickson & Kim, 1990). Peptidases located extracellularly in the blood or other extracellular compartments of the body often play regulatory roles in carefully controlled processes, such as blood clotting, fibrinolysis, complement activation, fertilization, and hormone production. Intracellularly located proteases exhibit a wide range of roles. They are found in the Endoplasmic Reticulum, the Golgi apparatus, or the lysosomes, among others. Their functions include the processing of peptide hormones, cytokines, and ubiquitin mediated proteolysis, among others (Fricker, 1988; Skidgel & Erdös, 1998; Fujiwara et al., 1999). 1.1 Types of proteases Several protease classification schemes have emerged.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002
    USOO6395889B1 (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002 (54) NUCLEIC ACID MOLECULES ENCODING WO WO-98/56804 A1 * 12/1998 ........... CO7H/21/02 HUMAN PROTEASE HOMOLOGS WO WO-99/0785.0 A1 * 2/1999 ... C12N/15/12 WO WO-99/37660 A1 * 7/1999 ........... CO7H/21/04 (75) Inventor: fish E. Robison, Wilmington, MA OTHER PUBLICATIONS Vazquez, F., et al., 1999, “METH-1, a human ortholog of (73) Assignee: Millennium Pharmaceuticals, Inc., ADAMTS-1, and METH-2 are members of a new family of Cambridge, MA (US) proteins with angio-inhibitory activity', The Journal of c: - 0 Biological Chemistry, vol. 274, No. 33, pp. 23349–23357.* (*) Notice: Subject to any disclaimer, the term of this Descriptors of Protease Classes in Prosite and Pfam Data patent is extended or adjusted under 35 bases. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/392, 184 Primary Examiner Ponnathapu Achutamurthy (22) Filed: Sep. 9, 1999 ASSistant Examiner William W. Moore (51) Int. Cl." C12N 15/57; C12N 15/12; (74) Attorney, Agent, or Firm-Alston & Bird LLP C12N 9/64; C12N 15/79 (57) ABSTRACT (52) U.S. Cl. .................... 536/23.2; 536/23.5; 435/69.1; 435/252.3; 435/320.1 The invention relates to polynucleotides encoding newly (58) Field of Search ............................... 536,232,235. identified protease homologs. The invention also relates to 435/6, 226, 69.1, 252.3 the proteases. The invention further relates to methods using s s s/ - - -us the protease polypeptides and polynucleotides as a target for (56) References Cited diagnosis and treatment in protease-mediated disorders.
    [Show full text]
  • NIH Public Access Author Manuscript Biochemistry
    NIH Public Access Author Manuscript Biochemistry. Author manuscript; available in PMC 2010 June 23. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Biochemistry. 2009 June 23; 48(24): 5731±5737. doi:10.1021/bi9003099. Neisseria gonorrhoeae Penicillin-Binding Protein 3 Demonstrates a Pronounced Preference for Nε-Acylated Substrates† Sridhar Peddi‡,§, Robert A. Nicholas∥, and William G. Gutheil‡,* ‡Division of Pharmaceutical Sciences, University of Missouri-Kansas City, 5005 Rockhill Road, Kansas City, Missouri 64110. ∥Department of Pharmacology, CB#7365, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7365. Abstract Penicillin-binding proteins (PBPs) are bacterial enzymes involved in the final stages of cell wall biosynthesis, and are the lethal targets of β-lactam antibiotics. Despite their importance, their roles in cell wall biosynthesis remain enigmatic. A series of eight substrates, based on variation of the pentapeptide Boc-L-Ala-γ-D-Glu-L-Lys-D-Ala-D-Ala, were synthesized to test specificity for three features of PBP substrates: 1) the presence or absence of an Nε-acyl group, 2) the presence of D- IsoGln in place of γ-D-Glu, and 3) the presence or absence of the N-terminal L-Ala residue. The capacity of these peptides to serve as substrates for Neisseria gonorrhoeae (NG) PBP3 was assessed. NG PBP3 demonstrated good catalytic efficiency (2.5 × 105 M−1sec−1) with the best of these substrates, with a pronounced preference (50-fold) for Nε-acylated substrates over Nε-nonacylated substrates. This observation suggests that NG PBP3 is specific for the ∼D-Ala-D-Ala moiety of pentapeptides engaged in cross-links in the bacterial cell wall, such that NG PBP3 would act after transpeptidase-catalyzed reactions generate the acylated amino group required for its specificity.
    [Show full text]
  • Structure of Human Aspartyl Aminopeptidase Complexed With
    Chaikuad et al. BMC Structural Biology 2012, 12:14 http://www.biomedcentral.com/1472-6807/12/14 RESEARCH ARTICLE Open Access Structure of human aspartyl aminopeptidase complexed with substrate analogue: insight into catalytic mechanism, substrate specificity and M18 peptidase family Apirat Chaikuad1, Ewa S Pilka1, Antonio De Riso2, Frank von Delft1, Kathryn L Kavanagh1, Catherine Vénien-Bryan2, Udo Oppermann1,3 and Wyatt W Yue1* Abstract Backround: Aspartyl aminopeptidase (DNPEP), with specificity towards an acidic amino acid at the N-terminus, is the only mammalian member among the poorly understood M18 peptidases. DNPEP has implicated roles in protein and peptide metabolism, as well as the renin-angiotensin system in blood pressure regulation. Despite previous enzyme and substrate characterization, structural details of DNPEP regarding ligand recognition and catalytic mechanism remain to be delineated. Results: The crystal structure of human DNPEP complexed with zinc and a substrate analogue aspartate-β- hydroxamate reveals a dodecameric machinery built by domain-swapped dimers, in agreement with electron microscopy data. A structural comparison with bacterial homologues identifies unifying catalytic features among the poorly understood M18 enzymes. The bound ligands in the active site also reveal the coordination mode of the binuclear zinc centre and a substrate specificity pocket for acidic amino acids. Conclusions: The DNPEP structure provides a molecular framework to understand its catalysis that is mediated by active site loop swapping, a mechanism likely adopted in other M18 and M42 metallopeptidases that form dodecameric complexes as a self-compartmentalization strategy. Small differences in the substrate binding pocket such as shape and positive charges, the latter conferred by a basic lysine residue, further provide the key to distinguishing substrate preference.
    [Show full text]
  • Molecular Markers of Serine Protease Evolution
    The EMBO Journal Vol. 20 No. 12 pp. 3036±3045, 2001 Molecular markers of serine protease evolution Maxwell M.Krem and Enrico Di Cera1 ment and specialization of the catalytic architecture should correspond to signi®cant evolutionary transitions in the Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Box 8231, St Louis, history of protease clans. Evolutionary markers encoun- MO 63110-1093, USA tered in the sequences contributing to the catalytic apparatus would thus give an account of the history of 1Corresponding author e-mail: [email protected] an enzyme family or clan and provide for comparative analysis with other families and clans. Therefore, the use The evolutionary history of serine proteases can be of sequence markers associated with active site structure accounted for by highly conserved amino acids that generates a model for protease evolution with broad form crucial structural and chemical elements of applicability and potential for extension to other classes of the catalytic apparatus. These residues display non- enzymes. random dichotomies in either amino acid choice or The ®rst report of a sequence marker associated with serine codon usage and serve as discrete markers for active site chemistry was the observation that both AGY tracking changes in the active site environment and and TCN codons were used to encode active site serines in supporting structures. These markers categorize a variety of enzyme families (Brenner, 1988). Since serine proteases of the chymotrypsin-like, subtilisin- AGY®TCN interconversion is an uncommon event, it like and a/b-hydrolase fold clans according to phylo- was reasoned that enzymes within the same family genetic lineages, and indicate the relative ages and utilizing different active site codons belonged to different order of appearance of those lineages.
    [Show full text]
  • 1 ICR-Geneset Gene List
    ICR-geneset Gene List. IMAGE ID UniGene Locus Name Cluster 20115 Hs.62185 SLC9A6 solute carrier family 9 (sodium/hydrogen exchanger), isoform 6 21738 21899 Hs.78353 SRPK2 SFRS protein kinase 2 21908 Hs.79133 CDH8 cadherin 8, type 2 22040 Hs.151738 MMP9 matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase) 22411 Hs.183 FY Duffy blood group 22731 Hs.1787 PHRET1 PH domain containing protein in retina 1 22859 Hs.356487 ESTs 22883 Hs.150926 FPGT fucose-1-phosphate guanylyltransferase 22918 Hs.346868 EBNA1BP2 EBNA1 binding protein 2 23012 Hs.158205 BLZF1 basic leucine zipper nuclear factor 1 (JEM-1) 23073 Hs.284244 FGF2 fibroblast growth factor 2 (basic) 23173 Hs.151051 MAPK10 mitogen-activated protein kinase 10 23185 Hs.289114 TNC tenascin C (hexabrachion) 23282 Hs.8024 IK IK cytokine, down-regulator of HLA II 23353 23431 Hs.50421 RB1CC1 RB1-inducible coiled-coil 1 23514 23548 Hs.71848 Human clone 23548 mRNA sequence 23629 Hs.135587 Human clone 23629 mRNA sequence 23658 Hs.265855 SETMAR SET domain and mariner transposase fusion gene 23676 Hs.100841 Homo sapiens clone 23676 mRNA sequence 23772 Hs.78788 LZTR1 leucine-zipper-like transcriptional regulator, 1 23776 Hs.75438 QDPR quinoid dihydropteridine reductase 23804 Hs.343586 ZFP36 zinc finger protein 36, C3H type, homolog (mouse) 23831 Hs.155247 ALDOC aldolase C, fructose-bisphosphate 23878 Hs.99902 OPCML opioid binding protein/cell adhesion molecule-like 23903 Hs.12526 Homo sapiens clone 23903 mRNA sequence 23932 Hs.368063 Human clone 23932 mRNA sequence 24004
    [Show full text]
  • Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases
    International Journal of Molecular Sciences Review Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases Peter Goettig Structural Biology Group, Faculty of Molecular Biology, University of Salzburg, Billrothstrasse 11, 5020 Salzburg, Austria; [email protected]; Tel.: +43-662-8044-7283; Fax: +43-662-8044-7209 Academic Editor: Cheorl-Ho Kim Received: 30 July 2016; Accepted: 10 November 2016; Published: 25 November 2016 Abstract: Posttranslational modifications are an important feature of most proteases in higher organisms, such as the conversion of inactive zymogens into active proteases. To date, little information is available on the role of glycosylation and functional implications for secreted proteases. Besides a stabilizing effect and protection against proteolysis, several proteases show a significant influence of glycosylation on the catalytic activity. Glycans can alter the substrate recognition, the specificity and binding affinity, as well as the turnover rates. However, there is currently no known general pattern, since glycosylation can have both stimulating and inhibiting effects on activity. Thus, a comparative analysis of individual cases with sufficient enzyme kinetic and structural data is a first approach to describe mechanistic principles that govern the effects of glycosylation on the function of proteases. The understanding of glycan functions becomes highly significant in proteomic and glycomic studies, which demonstrated that cancer-associated proteases, such as kallikrein-related peptidase 3, exhibit strongly altered glycosylation patterns in pathological cases. Such findings can contribute to a variety of future biomedical applications. Keywords: secreted protease; sequon; N-glycosylation; O-glycosylation; core glycan; enzyme kinetics; substrate recognition; flexible loops; Michaelis constant; turnover number 1.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,824 B2 Ramseier Et Al
    USOO8603824B2 (12) United States Patent (10) Patent No.: US 8,603,824 B2 Ramseier et al. (45) Date of Patent: Dec. 10, 2013 (54) PROCESS FOR IMPROVED PROTEIN 5,399,684 A 3, 1995 Davie et al. EXPRESSION BY STRAIN ENGINEERING 5,418, 155 A 5/1995 Cormier et al. 5,441,934 A 8/1995 Krapcho et al. (75) Inventors: Thomas M. Ramseier, Poway, CA 5,508,192 A * 4/1996 Georgiou et al. .......... 435/252.3 (US); Hongfan Jin, San Diego, CA 5,527,883 A 6/1996 Thompson et al. (US); Charles H. Squires, Poway, CA 5,558,862 A 9, 1996 Corbinet al. 5,559,015 A 9/1996 Capage et al. (US) 5,571,694 A 11/1996 Makoff et al. (73) Assignee: Pfenex, Inc., San Diego, CA (US) 5,595,898 A 1/1997 Robinson et al. 5,610,044 A 3, 1997 Lam et al. (*) Notice: Subject to any disclaimer, the term of this 5,621,074 A 4/1997 Bjorn et al. patent is extended or adjusted under 35 5,622,846 A 4/1997 Kiener et al. 5,641,671 A 6/1997 Bos et al. U.S.C. 154(b) by 471 days. 5,641,870 A 6/1997 Rinderknecht et al. 5,643,774 A 7/1997 Ligon et al. (21) Appl. No.: 11/189,375 5,662,898 A 9/1997 Ligon et al. (22) Filed: Jul. 26, 2005 5,677,127 A 10/1997 Hogan et al. 5,683,888 A 1 1/1997 Campbell (65) Prior Publication Data 5,686,282 A 11/1997 Lam et al.
    [Show full text]
  • Mouse Carboxypeptidase M / CPM Protein (His Tag)
    Mouse Carboxypeptidase M / CPM Protein (His Tag) Catalog Number: 50990-M08H General Information SDS-PAGE: Gene Name Synonym: 1110060I01Rik; 5730456K23Rik; AA589379; E030045M14Rik Protein Construction: A DNA sequence encoding the extracellular domain of mouse CPM isoform 1 (Q80V42-1) (Met 1-His 422), without the propeptide, was fused with a C- terminal polyhistidine tag. Source: Mouse Expression Host: HEK293 Cells QC Testing Purity: > 97 % as determined by SDS-PAGE Bio Activity: Protein Description Measured by its ability to release Larginine from BenzoylAlaArg, with Carboxypeptidase M, also known as CPM, is a membrane-bound detection of the arginine amino group by ophthaldialdehyde. The arginine/lysine carboxypeptidase which is a member of the specific activity is >40,000 pmoles/min/μg. carboxypeptidases family. These enzymes remove C-terminal amino acids from peptides and proteins and exert roles in the physiological processes Endotoxin: of blood coagulation/fibrinolysis, inflammation, food digestion and pro- hormone and neuropeptide processing. Among the carboxypeptidases < 1.0 EU per μg of the protein as determined by the LAL method CPM is of particular importance because of its constitutive expression in an active form at the surface of specialized cells and tissues in the human Stability: body. CPM in the brain appears to be membrane-bound via a Samples are stable for up to twelve months from date of receipt at -70 ℃ phosphatidylinositol glycan anchor. CPM is widely distributed in a variety of tissues and cells. The amino acid sequence of CPM indicated that the C- Predicted N terminal: Leu 18 terminal hydrophobic region might be a signal for membrane attachment via a glycosylphosphatidylinositol (GPI) anchor.
    [Show full text]
  • The Nutrition and Food Web Archive Medical Terminology Book
    The Nutrition and Food Web Archive Medical Terminology Book www.nafwa.
    [Show full text]
  • Bioinformatics Analyses of Genomic Imprinting
    Bioinformatics Analyses of Genomic Imprinting Dissertation zur Erlangung des Grades des Doktors der Naturwissenschaften der Naturwissenschaftlich-Technischen Fakultät III Chemie, Pharmazie, Bio- und Werkstoffwissenschaften der Universität des Saarlandes von Barbara Hutter Saarbrücken 2009 Tag des Kolloquiums: 08.12.2009 Dekan: Prof. Dr.-Ing. Stefan Diebels Berichterstatter: Prof. Dr. Volkhard Helms Priv.-Doz. Dr. Martina Paulsen Vorsitz: Prof. Dr. Jörn Walter Akad. Mitarbeiter: Dr. Tihamér Geyer Table of contents Summary________________________________________________________________ I Zusammenfassung ________________________________________________________ I Acknowledgements _______________________________________________________II Abbreviations ___________________________________________________________ III Chapter 1 – Introduction __________________________________________________ 1 1.1 Important terms and concepts related to genomic imprinting __________________________ 2 1.2 CpG islands as regulatory elements ______________________________________________ 3 1.3 Differentially methylated regions and imprinting clusters_____________________________ 6 1.4 Reading the imprint __________________________________________________________ 8 1.5 Chromatin marks at imprinted regions___________________________________________ 10 1.6 Roles of repetitive elements ___________________________________________________ 12 1.7 Functional implications of imprinted genes _______________________________________ 14 1.8 Evolution and parental conflict ________________________________________________
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]